Vericel Corporation
VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple fullā¦ read more
Healthcare
Biotechnology
28 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$40.37
Price-5.10%
-$2.17
1Y
Price
Market Cap
$2.042b
Mid
Price/Earnings 3y Avg5y Avg
155.3x
Premium
Premium
Financials Overview
Key metrics over the past few years+12.1%
EBITDA Margin+7.5%
Net Profit Margin+28.8%
Free Cash Flow MarginRevenue
$258.717m
+9.1%
1y CAGR+16.4%
3y CAGR+13.6%
5y CAGREarnings
$13.082m
+26.3%
1y CAGR+177.6%
3y CAGR+102.3%
5y CAGREPS
$0.24
+20.0%
1y CAGR+161.9%
3y CAGR+91.7%
5y CAGRBook Value
$321.858m
$453.274m
Assets$131.416m
Liabilities$98.006m
DebtDebt to Assets
21.6%
4.1x
Debt to EBITDAFree Cash Flow
$42.721m
+835.2%
1y CAGR+212.6%
3y CAGR+146.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company